Toth Financial Advisory Corp grew its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 7.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,883 shares of the company’s stock after purchasing an additional 4,178 shares during the quarter. AbbVie makes up approximately 1.7% of Toth Financial Advisory Corp’s portfolio, making the stock its 12th largest holding. Toth Financial Advisory Corp’s holdings in AbbVie were worth $16,711,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of ABBV. Whalen Wealth Management Inc. grew its stake in AbbVie by 9.4% in the 3rd quarter. Whalen Wealth Management Inc. now owns 4,049 shares of the company’s stock worth $1,059,000 after acquiring an additional 349 shares during the period. Retirement Wealth Solutions LLC boosted its holdings in shares of AbbVie by 815.8% during the third quarter. Retirement Wealth Solutions LLC now owns 1,740 shares of the company’s stock worth $455,000 after purchasing an additional 1,550 shares during the last quarter. Cooper Financial Group grew its position in shares of AbbVie by 23.0% in the third quarter. Cooper Financial Group now owns 14,096 shares of the company’s stock valued at $3,687,000 after purchasing an additional 2,636 shares during the period. Elm3 Financial Group LLC acquired a new position in AbbVie in the third quarter valued at $449,000. Finally, Canandaigua National Trust Co of Florida acquired a new position in AbbVie in the third quarter valued at $697,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by corporate insiders.
AbbVie Trading Down 1.0%
AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 13.93 earnings per share for the current year.
AbbVie Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is 195.48%.
Analyst Ratings Changes
ABBV has been the topic of a number of research analyst reports. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. HSBC increased their price objective on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Oppenheimer raised their target price on shares of AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Citigroup upped their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Finally, Leerink Partners increased their price target on shares of AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $276.11.
Get Our Latest Stock Analysis on AbbVie
Key AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: FDA breakthrough designations strengthen the oncology pipeline. The FDA granted two Breakthrough Therapy Designations for investigational telisotuzumab adizutecan (Temab-A/ABBV-400) in colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory discussions for the company’s next-generation antibody-drug conjugate. AbbVie Temab-A FDA breakthrough designations
- Positive Sentiment: Epkinly produced a significant Phase 3 result. AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The data could support broader adoption and a stronger competitive position against Roche’s Polivy. AbbVie and Genmab Epkinly Phase 3 results
- Positive Sentiment: Analysts remain constructive. Cantor Fitzgerald raised its AbbVie price target to $290 from $285 and maintained an overweight rating. HSBC has also outlined a bullish case with a $315 target, providing additional support for investor sentiment.
- Neutral Sentiment: Broader market factors may be limiting gains. Rising Treasury yields and uncertain equity-market conditions are creating pressure across stocks, even as healthcare companies benefit from defensive characteristics.
- Negative Sentiment: Dividend sustainability remains a concern. Recent commentary highlighted AbbVie’s reported payout ratio near 190%, raising questions about how comfortably earnings cover the dividend. The concern may weigh on income-focused investors, although adjusted earnings and cash flow can differ from reported net income.
- Negative Sentiment: Valuation leaves less room for disappointment. With ABBV trading near its 52-week high and at an elevated earnings multiple, investors may be taking profits or demanding stronger evidence that new medicines can offset long-term Humira-related pressures.
AbbVie Company Profile
AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.
The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.
AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.
Read More
- Five stocks we like better than AbbVie
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
- This Space ETF Offers SpaceX Exposure—But Investors Are Paying for the Volatilit
- Does Lemonade’s Growth Signal Profits Ahead?
- These 3 ETFs Could Benefit From the Parts of Inflation That Won’t Go Away
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
